Researchers from the Josep Carreras Leukaemia Research Institute, led by Dr. Manel Esteller, have published a dataset covering thousands of methylated sites from hundreds of cancer-derived cultured cells, covering many leukaemias, lymphomas and myelomas, from humans and mice. With this data, any researcher can access the epigenetic signature of these tumours for research and clinical purposes. Researchers from the Josep Carreras Leukaemia Research Institute, led by Dr. Manel Esteller, have published a dataset covering thousands of methylated sites from hundreds of cancer-derived cultured cells, covering many leukaemias, lymphomas and myelomas, from humans and mice. With this data, any researcher can access the epigenetic signature of these tumours for research and clinical purposes.

Cancer cells on the surface are thought to have natural advantages compared to cells deep within, which is why scientists have hypothesised tumours grow more in their periphery than in the core. A study published today in the journal eLife found the opposite is true: tumours grow throughout their mass. The findings challenge the idea that a tumour is a ‘two-speed’ entity.

Min Li, Ph.D., a George Lynn Cross Professor of Medicine, Surgery and Cell Biology at the University of Oklahoma College of Medicine and Associate Director for Global Oncology at OU Health Stephenson Cancer Center, will receive the 2024 Palade Prize from the International Association of Pancreatology.

Researchers at the Medical University of South Carolina and the University of Florida recently collaborated on a novel, highly specific strategy to treat type 1 diabetes (T1D) using a tagged beta cell transplant in tandem with localized immune protection provided by specialized immune cells also tagged with a complementary but inert targeting molecule.

Positive results from a clinical trial in adults with grade 2 glioma were a Late-Breaking Abstract at the Society of Neuro-Oncology (SNO) 2024 Annual Meeting. The results have an immediate clinical impact, as this is the first evidence from a randomized phase 3 study that temozolomide chemotherapy improves long-term survival for these patients. Radiation therapy plus chemotherapy is the routine initial treatment for patients with this slow-growing form of brain cancer. Some receive PCV chemotherapy based on evidence of benefit from a prior trial. Others receive temozolomide, a chemotherapy pill, because it is less toxic for patients and more manageable for oncologists to administer. However, until E3F05, there was no supporting evidence in grade 2 gliomas that temozolomide was beneficial. The 10-year survival rate was 70% with the combined treatment compared to 47% with radiation alone. 

Colorectal cancer screening is an effective tool for catching the disease early when it's most treatable, yet it is underutilized at federally qualified health centers (FQHC). A new study by UNC Lineberger Comprehensive Cancer Center researchers demonstrated that a targeted intervention that paired mailing at-home colorectal cancer screening kits with coordinated follow-up tripled screening completion rates compared to usual care at FQHCs